LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway

H Hasegawa1, Y Yamada1, K Tsukasaki2, N Mori1, K Tsuruda1, D Sasaki1, T Usui1, A Osaka1, S Atogami1, C Ishikawa3,4, Y Machijima1, S Sawada1, T Hayashi3, Y Miyazaki2 and S Kamihira1

1Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; 2Department of Hematology, Atomic Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; 3Division of Molecular Virology and Oncology, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan; 4Transdisciplinary Research Organization Subtropics Island Studies, University of the Ryukyus, Nishihara, Okinawa, Japan and 5Department of Pathology, Nagasaki University Hospital, Nagasaki, Japan

Adult T-cell leukemia/lymphoma (ATLL), an aggressive neoplasm etiologically associated with human T-lymphotropic virus type-I (HTLV-1), is resistant to treatment. In this study, we examined the effects of a new inhibitor of deacetylase enzymes, LBH589, on ATLL cells. LBH589 effectively induced apoptosis in ATLL-related cell lines and primary ATLL cells and reduced the size of tumors inoculated in SCID mice. Analyses, including with a DNA microarray, revealed that neither death receptors nor p53 pathways contributed to the apoptosis. Instead, LBH589 activated an intrinsic pathway through the activation of caspase-2. Furthermore, small interfering RNA experiments targeting caspase-2, caspase-9, RAIDD, p53-induced protein with a death domain (PIDD) and RIPK1 (RIP) indicated that activation of RAIDD is crucial and an event initiating this pathway. In addition, LBH589 caused a marked decrease in levels of factors involved in ATLL cell proliferation and invasion such as CCR4, IL-2R and HTLV-1 HBZ-SI, a spliced form of the HTLV-1 basic zipper factor HBZ. In conclusion, we showed that LBH589 is a strong inducer of apoptosis in ATLL cells and uncovered a novel apoptotic pathway initiated by activation of RAIDD.

Leukemia (2011) 25, 575–587; doi:10.1038/leu.2010.315; published online 18 January 2011

Keywords: LBH589; apoptosis; adult T-cell leukemia; caspase-2; RAIDD

Introduction

There is evidence that gene expression governed by epigenetic changes is crucial to the pathogenesis of cancer.1 Histone deacetylases are enzymes involved in the remodeling of chromatin, and have a key role in the epigenetic regulation of gene expression. In addition, the activity of non-histone proteins can be regulated through histone deacetylase-mediated hypoacetylation.2 Deacetylase inhibitors (DACi) induce the hyperacetylation of non-histone proteins, as well as nucleosomal histones resulting in the expression of repressed genes involved in growth arrest, terminal differentiation and/or apoptosis among cancer cells.3,4 Several classes of DACi have been found to have potent anticancer effects in preclinical studies.2 Despite a consensus on the importance of apoptosis to the effect of these drugs, different apoptotic mechanisms have been reported.5 For instance, even the contribution of caspases to DACi-induced apoptosis is quite controversial.6–8

There are two general apoptotic pathways, the receptor (extrinsic) pathway and the mitochondrial (intrinsic) pathway.9 The extrinsic pathway requires activation of caspase-8, which results in activation of the zymogens of executioner caspses such as caspase-3, eventually leading to cleavage of poly ADP-ribose polymerase (PARP). Proteolytic caspase-8 can further activate BH3-interacting domain death agonist (BID), and cleaved BID moves to the mitochondria where it triggers the release of cytochrome-c. In the intrinsic pathway, death signals lead to changes in the mitochondrial outer membrane’s permeability, subsequently releasing cytochrome-c, which forms an apoptosome with caspase-9, eventually activating executioner caspses.10 LAQ824 and the more potent and newly developed DACi analog LBH589 are now under clinical investigation as a therapeutic agent for several kinds of cancer.2,4 One unique feature of these drugs is their role in the regulation of heat shock protein 90kDa-α (HSP90) and degradation of HSP90 client proteins such as bcr–abl in chronic myelogenous leukemia and fms-related tyrosine kinase 3 in acute myeloid leukemia.11–15

Adult T-cell leukemia/lymphoma (ATLL) is a neoplasm of mature T-lymphocyte origin etiologically associated with human T-lymphotropic virus type-I (HTLV-1) and is known to be resistant to standard anticancer therapies.16 Previous findings suggest that the viral protein HTLV-1 Tax interferes with most DNA repair mechanisms, preventing cell cycle arrest and apoptosis, and contributing to the early stages of ATLL.17,18 In addition, the novel viral protein HTLV-1 basic zipper factor (HBZ) and its spliced form (HBZ SP1RNA or HBZ-SI), which are encoded by the minus-strand RNA of the HTLV-1 genome, have been identified recently.19–23 These proteins are thought to be functional and expected to be closely involved in the late stages of ATLL.24 ATLL is generally classified into four clinical subtypes: acute, chronic, smoldering and lymphoma. Although several approaches have been reported, combination chemotherapy is still the treatment of choice for newly diagnosed acute and lymphoma-type ATLL. Patients with aggressive ATLL have a median survival period of 13 months, indicating limitations in the treatment of ATLL.25,26 In this study, we examined the effects of LBH589 on ATLL cells in vitro and in vivo, and investigated the pathways or factors contributing to the LBH589-induced ATLL cell death.

Materials and methods

Cell preparation

The ATLL-derived cell lines ST1, KOB, LM-Y1, LM-Y2, KK1 and SO4 were established in our laboratory from ATLL patients27,28 and maintained in RPMI 1640 medium supplemented with
10% fetal bovine serum and 0.5 U/ml of interleukin-2 (kindly provided by Takeda Pharmaceutical Company, Ltd., Osaka, Japan). The HTLV-1-infected T-cell lines MT2 and HuT102,29,30 human T-cell leukemia cell line Jurkat and erythromyeloblastoid cell line K562 were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum. The ST1, KOB, LM-Y1, MT2 and HuT102 cells have the wild-type p53.31 Primary leukemia cells from eight patients with acute-type ATLL were also analyzed. The diagnosis of ATLL and preparation of peripheral blood mononuclear cells from patients with ATLL and normal healthy donors were described previously.28 Each patient’s sample contained more than 80% leukemia cells at the time of analysis. After approval by the Ethics Committee of the University of the Ryukyus and was approved by the Animal Care and Use Committee of the same university.

Chemicals and cell proliferation assay

Chemicals used in this study were LBH589 (kindly provided by Novartis Pharma AG., Basel, Switzerland), SAHA (Cayman Chemical, Ann Arbor, MI, USA), MG132 (Biomol Research Laboratories, Plymouth Meeting, PA, USA), LY294002 (Biomol), soluble tumor necrosis factor related apoptosis-inducing ligand (TRAIL) (Biomol), staurosporine (Merck, Darmstadt, Germany), the pan-caspase inhibitor z-VAD-fmk, the caspase-2 inhibitor Z-VDVAD-fmk and the caspase-9 inhibitor Z-LEHD (MBL, Nagoya, Japan). The cell proliferation assay (3-(4,5-dimethyl-thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt assay) was performed with a Cell Titer 96 AQueos Cell Proliferation Assay kit (Promega, Madison, WI, USA) according to the manufacturer’s directions.

In vivo experiments using SCID mice

Five-week-old female C.B-17/Scid-SCID mice obtained from Ryuku Biotec (Urasoe, Japan) were maintained in containment level 2 cabinets and provided with autoclaved food and water ad libitum. The mice were engrafted with 107 HuT102 cells by subcutaneous injection in the post-auricular region and randomly placed into two cohorts of five animals each that received vehicle or LBH589. Treatment was initiated on the day after cell injection. LBH589 was dissolved in distilled water at a concentration of 2 mg/ml, and 28 mg/kg body weight of LBH589 was administered by oral gavage three times a week. Control mice received the same volume of the vehicle only. Body weight and tumor numbers and size were monitored once a week. All mice were sacrificed on day 28, then the tumors were dissected out, and their weight was measured. After tumors were fixed for paraffin embedding and tissue sectioning, DNA fragmentation was evaluated by fluorometric assay (Takara Bio Inc., Shiga, Japan) according to the manufacturer’s instructions.

Flow cytometric analysis

To evaluate apoptotic changes and the permeability of the mitochondrial outer membrane, we used an Annexin-V and PI Kit (Bender Medsystems, Vienna, Austria) and a Mitochondrial Membrane Potential Assay Kit (5, 5′, 6, 6′-tetrachloro-1, 1′, 3′, 3′-tetrathylbenzimidazol-carboxyanine iodide detection) (Cayman Chemical), respectively. Activities of caspase-8 and -9 were determined by fluorometric assay (MBL) according to the manufacturer’s instructions. The cell-surface expression of death receptors (DRs), CCC4 and IL-2R was examined by flow cytometric analysis using anti-tumor necrosis factor-RI (MBL), anti-CD95 (BD Biosciences, San Diego, CA, USA), anti-DR5 (Alexis Biochemicals, San Diego, CA, USA), anti-CC44 and anti-CD25 (BD) monoclonal antibodies. Mouse IgG1 (DAKO, Kyoto, Japan) was used as a negative control. All experiments were performed using a FACSCalibur flow cytometer and Cellquest software (BD).

Western blotting, immunoprecipitation and antibodies

Western blotting was performed as described previously.31 The analysis was performed using antibodies to p53 (DO-1), MDM2 (Ab-1), FADD, PUMA and NOXA (Merck), phospho-AKT, AKT, caspase-8, 9 and 3, cleaved caspase-9, cleaved PARP, BID, BAX, Bcl-xl, cytochrome-c, p21 and acetylated-Lysin (Cell Signaling Technology, Beverly, MA, USA), p53-induced protein with a death domain (PIDD) (LifeSpan Biosciences, Seattle, WA, USA), caspase-2 (11B4) and c-FLIP (Dave-2) (Alexis), RAIDD and TRADD (MBL), survivin (R&D systems Inc., Minneapolis, MN, USA), acetylated-histone-H3 and -H4, and Bcl-2 (Upstate Biotechnology, Waltham, MA, USA), RIP and XIAP (BD), HBZ (kindly provided by Dr JM Mesnard and HBZ-2), Tax,31 acetylated-tubulin, a-tubulin and b-actin (Sigma Chemicals, St Louis, MO, USA). In the immunoprecipitation assay, protein A-Sepharose beads (Sigma), HSP90 antibody (StressGen Biotechnologies Corporation, Victoria, BC, Canada) and RAIDD antibody (LifeSpan Biosciences) were used.

Immunohistochemistry

After tumors were fixed for paraffin embedding and tissue sectioning, immunohistochemical staining for acetylated-histone-H3 and -H4 was performed. The deparaffinized slides were pretreated with DAKO Target Retrieval Solution (pH 9) (DAKO), and heated in a water bath at 95 °C for 40 min. For all stains, the endogenous peroxidase was quenched by 3% H2O2 for 15 min. Sections were then placed in 0.5% nonfat dry milk for 30 min at room temperature. The primary antibodies used were anti-acetylated-histone-H3 and -H4 (Cell Signaling). They were allowed to react for 1 h at room temperature, and then the DAKO EnVision - Dual Link System-HRP (DAKO) was applied using diaminobenzidine as the chromogen, following the manufacturer’s directions.

Proteasome activity assay

The proteolytic activity of the 20S proteasome was evaluated with the Biomol AK-740 QuantiZyme Assay System (Biomol) following the manufacturers’ instructions, which detects the release of the free 7-amino-4-methylcoumarin fluorophore, upon cleavage of the fluorogenic peptide Suc-LLVYAMC.

DNA microarray analysis

Total RNA from cells was extracted using ISOGEN (Nippon Gene, Toyama, Japan) and purified with a Message Clean kit.
Supplementary Table 1.
mix (Roche) according to the directions. We designed specific
caspase-2, caspase-9, RAIDD, PIDD and PBGD were performed
in 100

mention and each siRNA experiment was performed in triplicate.

(siRNA against each target. Cells were used 24 h after transfec-
(Supplementary Figure 2), we eventually selected a set of #1
each siRNA by monitoring the target's mRNA and protein
Select Validated siRNA s16651 (#1), s11652 (#2) and s16653
Caspase-2: Silencer Select Validated siRNA s2412 (#1), s2410
Different small interfering RNA (siRNA) against each target.

Results
LBH589 causes acetylation of histones and non-histone
proteins in ATLL cells
Hydroxamate-based DACi including LBH589 induce hyper-
acetylation of histones H3/H4 and z-tubulin.7,4 Recent reports
also indicated that LAQ824 and LBH589 can cause acetylation
of HSP90 and the disruption of its chaperone function, resulting
in repression of HSP90 client proteins including AKT.12,35 We
first confirmed that LBH589 was very effective in increasing the
acetylation of histones H3/H4 and z-tubulin in ATLL-related cell
lines (Figure 1a). As expected, LBH589 also caused acetylation
of HSP90 in ST1, KOB and KK1 cells and significantly reduced
the expression of phospho-AKT (Figures 1b and c).

Figure 1 LBH589 causes acetylation of histones and non-histone
proteins in adult T-cell leukemia/lymphoma (ATLL) cells. Cells were
treated with either vehicle or the indicated concentrations of LBH589
for 24 h. Whole-cell lysate was prepared, and (a) and (c) western
blotting was performed. (b) For each sample, 100 mg of cell lysate
was used for immunoprecipitation with a monoclonal antibody to heat
shock protein 90kDa z (HSP-90), and western blotting was performed.

Treatmentsubcutaneous tumors with LBH589
We examined whether LBH589 is also effective against ATLL cells
in the vivo setting, by using SCID mice transplanted with
HuT102 cells. Ten mice were inoculated, five of which were

Leukemia
LBH589 induces apoptosis in ATLL cells.

Hasegawa et al.

LBH589 reduces the volume of tumors more than 70% (Figure 3a). The mean tumor weight of LBH589-treated mice was significantly lower than that of control mice (Figure 3b). Immunohistochemical staining confirmed that LBH589 was very effective in increasing the acetylation of histones H3/H4 in tumors of treated mice (Figure 3c). We further confirmed by a TUNEL assay that LBH589 caused evident apoptosis in transplanted tumors (Figure 3d).

Analysis of the extrinsic pathway in LBH589-induced apoptosis

DACi are reported to activate the extrinsic pathway, in many cases, in cooperation with (DRs).2 Among typical DRs, DR5 was expressed in ATLL-related cell lines28 but tumor necrosis factor-R1 mostly was not (not shown) and there was no change after LBH589 treatment (not shown). LBH589 rather reduced Fas expression in ST1, LM-Y1 and HuT102 cells (Figure 4a). In typical DR-mediated apoptosis (Jurkat + TRAIL), both extrinsic and intrinsic pathways are activated including cleavage of BID, which was not observed in K562 cells treated with 12 nM of LBH589 (Figure 4c). In ATLL cell lines, western blotting revealed no bands of cleaved caspase-8 on treatment with LBH589 (Figure 4b). This was accompanied by slight changes in FADD and BID expression (Figure 4b). In contrast, LBH589 reduced the expression of FLIP proteins in HuT102 and KK1 cells (Figure 4b). Fluorometric analysis eventually showed that LBH589 little
LBH589 reduces tumors inoculated in SCID mice. HuT102 cells (10^7 per mouse) were injected subcutaneously into SCID mice. The mice (five per group) were treated with either vehicle or LBH589. Treatment was initiated on the day after inoculation. Tumor volume and weight were monitored on the indicated days after the injection of cells. (a) Serial changes in tumor volume in treated and untreated mice. Data are the mean ± s.d. for five mice each. Mann–Whitney’s U-test was used to compare results with control values. (b) Tumors removed from untreated mice and LBH589-treated mice on day 28 after cell inoculation were weighed. (c) Immunohistochemical staining shows the acetylation of histones H3/H4 in tumors of treated mice. (d) TUNEL assays show apoptotic cells in tumors from mice treated with LBH589 compared with the control mouse. Magnification, × 40.

activated caspase-8 in ATLL-related cell lines in contrast to caspase-9 (Figure 4d). These results suggest that LBH589 does not activate the extrinsic pathway in ATLL-related cell lines.

**LBH589 induces apoptosis in ATLL cells by activating the intrinsic pathway**

Next, we investigated the changes in permeability of the mitochondrial membrane in cells treated with LBH589 by using the 5, 5′, 6, 6′-tetrachloro-1, 1′, 3, 3′-tetraethylbenzimidazolocarbocyanine iodide dye. The percentage of cells with decreased red fluorescence was increased from 73 to 81% and from 11 to 76% in ST1 and HuT102 cells, respectively (Figure 4e). Time course analyses of these changes are shown in Figure 4f. Furthermore, the release of cytochrome-c from mitochondria to the cytosol was detected by western blotting (Figure 4g). The activation of caspase-9 was confirmed by the appearance of cleaved caspase-9 and by a fluorometric analysis, which showed a three–eightfold increase after treatment with LBH589 (Figures 4b and d). The bands of cleaved caspase-3 and cleaved PARP, as a result of apoptosis, were clearly observed (Figure 4b). Collectively, these results suggest that the major mechanism of LBH589-induced apoptosis is activation of the intrinsic pathway.

**Contribution of caspase-9 and/or AKT in LBH589-induced apoptosis**

Interestingly, the band for pro-caspase-9 did not decrease in intensity in spite of its consumption but rather increased on treatment with LBH589 (Figure 4b). AKT has been shown to downregulate the expression of caspase-9 via direct phosphorylation and LBH589 significantly reduced the expression of phospho-AKT (Figure 1c). Then, we used a typical PI3K/AKT inhibitor, LY294002, to investigate the impact of AKT’s inactivation in LBH-induced apoptosis. ATLL cell lines with phospho-AKT actually underwent apoptosis and showed a decrease in phospho-AKT on treatment with LY294002. In this setting, however, the expression of caspase-9 was not upregulated (not shown). Furthermore, we performed transfection experiments with myr-AKT. The expression levels of phospho-AKT were not decreased by LBH589 in myr-AKT-transfected HuT102 cells (Supplementary Figure 1B). In this setting, we found that the percentage of Annexin-V-positive cells was decreased in myr-AKT cells (Supplementary Figure 1A). Expression levels of cleaved caspase-3 in LBH589-treated myr-AKT cells were moderately lower than those in mock-transfected cells (Supplementary Figure 1B). However, expression levels of other key molecules including caspase-9 were not altered (Supplementary Figure 1B). These results suggest that the LBH589-induced decrease in phospho-Akt levels is not an event upstream of the LBH589-induced accumulation of caspase-9 but partly contributes to the pro-apoptotic effects of LBH589.

**Microarray analysis**

We performed a DNA microarray analysis using HuT102 and LM-Y1 cells and compared gene expression profiles between cells treated with LBH589 and cells left untreated focusing on how the intrinsic pathway is activated during LBH589-induced apoptosis (Table 1). Among commonly observed changes, an upregulation of cytochrome-c expression and a downregulation of p53 expression were remarkable. An upregulation of caspase-9 expression and a downregulation of FAS expression, were in accord with results of western blotting and flow cytometric analysis, respectively (Figures 4a and b). Taking into consideration the results of the microarray analysis, we performed further studies focusing on three different groups: ATLL-characteristic, p53-related and caspase-2-related proteins.

**Analysis of proteins characteristic of ATLL cells**

We first focused on CCR4 and IL-2R, which were remarkably affected by LBH589 (Table 1). A majority of ATLL cells...
LBH589 induces apoptosis in ATLL cells

H. Hasegawa et al.

Figure 4: Analysis of the apoptotic pathway in LBH589-induced cell death. Cells were treated with either vehicle or the indicated concentrations of LBH589 for 24–48 h. After cells were harvested, flow cytometric analysis (FCM) (a, d, e, and f) or western blotting (b and g) was performed. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (100 ng/ml)-treated Jurkat cells were used as a positive control for typical apoptosis and LBH589 (25 nM)-treated K562 cells were used as a negative control. (a) Changes in expression of Fas were indicated using RFI (the ratio of mean fluorescence intensity for specific staining to that for control staining). (d) Activities of caspases. Cells were incubated with the IETD-FMK for caspase-8, conjugated to FITC (FITC-IETD-FMK) or the LEHD-FMK for caspase-9, conjugated to FITC (FITC-LEHD-FMK) and analyzed using FCM. Comparison of the fluorescence intensity in the treated sample with that of the untreated control allows determination of the fold increase in activity of each caspase. (e and f) Mitochondrial membrane permeability. Cells were incubated with the JC-1 dye and analyzed using FCM. The percentage of cells with low JC-1 red fluorescence was evaluated. (b, c, and g) Western blotting was performed using whole-cell lysate (b and c) or a cytosolic fraction (g) prepared as described in Materials and methods.

Consistently express CCR4, which contributes to tumor cell progression and/or invasion. ATLL-related cell lines had high levels of CCR4, which were dramatically decreased by LBH589 treatment (Figure 5a). IL-2R is also known to be overexpressed in ATLL cells and is often used as a diagnostic marker for ATLL. LBH589 repressed the expression of IL-2R ~50% in the ATLL-related cell lines though levels were still extremely high (Figure 5b). Importantly, IL-2R is a typical gene whose promoter is activated by HTLV-1 Tax. Then, we investigated whether the suppression of Tax mRNA expression is also affected by LBH589. The effect depended on the cells examined. In cells with high Tax mRNA levels (KOB, MT2, and HuT102), the expression tendency to increase with LBH589 treatment, while in cells with relatively low Tax mRNA levels (LMY1, KK1 ST1, and SO4), it tended to decrease (Figure 5c). These results were consistent with those of western blotting (Figure 5c upper panel). The behavior of the HBZ mRNA was similar to that of the Tax mRNA; cells with high Tax levels tended to show an increase in HBZ mRNA on LBH589 treatment, while cells with lower Tax levels tended to exhibit a decrease (Figure 5d). In contrast, LBH589 significantly repressed HBZ-SI mRNA expression in ATLL-related cell lines except MT2 cells (Figure 5e). Protein levels of HBZ and HBZ-SI were not high in any cells examined and the expression profiles were approximately the same as those for the mRNA (Figures 5d and e). As NF-xB is constitutively activated in ATLL cells dependent on and/or independent of HTLV-1 Tax, the repression of NF-xB is an important mechanism in DACi-induced ATLL cell death. We examined the activities of NF-xB. However, repression of NF-xB by LBH589 was not commonly observed in ATLL-related cell lines (not shown).

LBH589-induced apoptosis in ATLL cells does not depend on the p53 pathway

Although p53 is an important inducer of the intrinsic apoptotic pathway, its gene expression was significantly decreased by LBH589 treatment (Table 1). To verify this phenomenon, we performed a luciferase assay with pG13-Luc using ST1, HuT102, KOB, and KK1 cells and found that activation of p53 had not occurred (not shown). Unexpectedly, LBH589 reduced the
LBH589 induces apoptosis in ATLL cells
H Hasegawa et al

Table 1  Microarray analysis of HuT102 cells

| Symbol | Gene Description                                                                 | Fold change |
|--------|----------------------------------------------------------------------------------|-------------|
|        |                                                                                  | HUT102      | LM-Y1      |
| SPP1   | Secreted phosphoprotein 1 (osteopontin, bone sialoprotein 1, early T-lymphocyte activation-1) | 6.4         | 9.4        |
| DHR52  | Dehydrogenase/reductase (SDR family) member-2                                    | 6.2         | 2.5        |
| SERPINB2 | Serpin peptidase inhibitor, clade B (ovalbumin), member-2                      | 5.6         | 3.8        |
| CASP9  | Caspase 9, apoptosis-related cysteine peptidase                                   | 3.9         | 1.7        |
| BTG2   | BTG family, member-2                                                             | 3.4         | 2.2        |
| CYCS   | Cytochrome-c, somatic                                                            | 3.4         | 2.1        |
| CLU    | Clusterin                                                                        | 3.1         | 2.1        |
| CTSB   | Cathepsin B                                                                      | 3.1         | 3.5        |
| GADD45B | Growth arrest and DNA damage inducible, beta                                      | 2.9         | 3.6        |
| PHLDA1 | Pleckstrin homology-like domain, family A, member-1                              | 2.9         | 2.0        |
| EFHC1  | EF-hand domain (C-terminal) containing 1                                         | 2.8         | 2.6        |
| IP6    | Interferon, alpha-inducible protein-6                                            | 2.7         | 2.2        |
| NLRP1  | NLR family, pyrin domain containing 1                                            | 2.7         | 1.1        |
| LOH11CR2A | Loss of heterozygosity, 11, chromosomal region 2, gene A       | 2.6         | 2.3        |
| RARRES3 | Retinoic acid receptor responder (tazarotene induced) 3                       | 2.5         | 2.5        |
| ARHGAP20 | Rhod GTPase activating protein 20                                               | 2.3         | 1.7        |
| BCL10  | B-cell CLL/lymphoma 10                                                           | 2.3         | 1.5        |
| BTG1   | B-cell translocation gene 1, anti-proliferative                                   | 2.3         | 1.4        |
| ACRV1C | Activin A receptor, type IC                                                      | 2.2         | 1.0        |
| FASLG  | Fas ligand (TNF superfamily, member-6)                                            | 2.2         | —          |
| RECK   | Reversion-inducing-cysteine-rich protein with kazal motifs                      | 2.2         | —          |
| SIAH2  | Seven in absentia homolog 2 (Drosophila)                                         | 2.2         | —          |
| APAF1  | Apoptotic peptidase-activating factor-1                                          | 2.1         | 1.5        |
| ATM    | Ataxia telangiectasia mutated (includes complementation groups A, C and D)       | 2.1         | —          |
| CRADD  | CASP2 and RIPK1 domain containing adaptor with death domain                      | 2.1         | 1.6        |
| RIPK1  | Receptor (TNFRSF)-interacting serine-threonine kinase-1                          | 2.1         | 1.3        |
| LTA    | Lymphotoxin alpha (TNF superfamily, member-1)                                    | 2.1         | 1.3        |
| ILT10  | Interleukin-10                                                                   | 2.1         | 1.3        |
| TNFRSF8 | Tumor necrosis factor receptor superfamily, member-8                            | 2.1         | —          |
| CCR4   | Chemokine (C-C motif) receptor 4                                                 | 2.3         | —          |
| IL2RA  | Interleukin-2 receptor, alpha                                                     | 2.3         | —          |
| TPS3   | Tumor protein p53 (Li-Fraumeni syndrome)                                         | 2.3         | —          |
| IKF1   | IKAROS family zinc finger-1 (Ikaros)                                             | 2.4         | —          |
| CCNB1  | Cdc2 cyclin B                                                                    | 3.3         | 3.8        |
| FAS    | Fas (TNF receptor superfamily, member-6)                                         | 3.3         | —          |
| MK67   | Antigen identified by monoclonal antibody Ki-67                                   | 3.2         | —          |
| CDC2   | Cell division cycle 2, G1 to S and G2 to M                                       | 3.2         | —          |
| PLK1   | Polo-like kinase 1 (Drosophila)                                                  | 3.0         | 1.4        |
| SULF1  | Sulfatase 1                                                                       | 3.0         | —          |
| BIRC5  | Baculoviral IAP repeat-containing 5 (survivin)                                    | 2.9         | 3.8        |
| CDK2AP1 | CDK2-associated protein-1                                                        | 2.9         | —          |
| AVEN   | Apoptosis, caspase activation inhibitor                                           | 2.9         | —          |
| MCM5   | Minichromosome maintenance complex component-5                                   | 2.9         | —          |
| CDC25A | Cell division cycle 25 homolog A (Schizosaccharomyces pombe)                     | 2.7         | —          |
| MYBL2  | v-myb Myeloblastosis viral oncogene homolog (avian)-like-2                       | 2.7         | —          |
| MDC2C  | v-myc Myelocytomatosis viral oncogene homolog (avian)                            | 2.7         | —          |
| BUB1B  | BUB1 budding inhibited by benomyl dizeaels 1 homolog beta (yeast)                 | 2.6         | 4.1        |
| CDC2A3 | Cell division cycle associated-3                                                 | 2.6         | —          |
| FAM    | Fas apoptotic inhibitory molecule                                                 | 2.6         | —          |
| ATF5   | Activating transcription factor-5                                                | 2.6         | —          |
| WEE1   | WEE1 homolog (Schizosaccharomyces pombe)                                         | 2.5         | —          |
| BCA1   | Branched chain aminotransferase 1, cytosolic                                     | 2.4         | —          |
| CCNA2  | Cyclin A2                                                                        | 2.4         | —          |
| STEAP3 | STEAP family member 3                                                            | 2.4         | —          |
| ZAK    | Sterile alpha motif and leucine zipper containing kinase AZK                      | 2.4         | —          |
| CCNB2  | Cyclin B2                                                                        | 2.3         | —          |
| FBXO5  | F-box protein-5                                                                  | 2.3         | —          |
| HMGB1  | High-mobility group box 1                                                        | 2.3         | —          |
| NEK6   | NIMA (neither in mitosis gene a)-related kinase-6                                | 2.3         | —          |
| RYR1   | Ryanodine receptor 1 (skeletal)                                                  | 2.3         | —          |
| SFRS2  | Splicing factor, arginine/serine-rich-2                                          | 2.3         | —          |
| AURKA  | Aurora kinase A                                                                  | 2.2         | —          |
| BCLAF1 | BCL2-associated transcription factor 1                                           | 2.2         | —          |
| CCR4   | Chemokine (C-C motif) receptor-4                                                 | 2.2         | —          |
| EZF9   | EZF transcription factor-8                                                       | 2.2         | —          |
| CDC45L | CDC45 cell division cycle 45-like (S. cerevisiae)                                 | 2.1         | 4.3        |
| CSE1L  | CSE1 chromosome segregation 1-like (yeast)                                       | 2.1         | —          |
| HK2    | Hexokinase-2                                                                     | 2.1         | —          |
| NME1   | Non-metastatic cells 1, protein (NM23A) expressed in                              | 2.1         | —          |

Abbreviation: TNF, tumor necrosis factor. HuT102 and LM-Y1 cells were treated with either vehicle or 50 nM of LBH589 for 24 h and DNA microarray analyses were performed. Among genes with changes in expression of at least 2.1-fold (log 2 ratio) in either direction in HuT102 cells, we picked those with known functions related to apoptosis, the cell cycle and cell proliferation.
expression of p53 in ST1 and KK1 as well as HuT102 cells without any accumulation of MDM2, which degrades p53 (Figure 6a). In contrast, the band of p21 was increased in intensity in these cell lines irrespective of their p53 status. Among apoptosis-related proteins downstream of p53, we found an increase in survivin, a decrease in XIAP, and no change in BAX, PUMA and Bcl-2 on treatment with LBH589 in ST1 or HuT102 cells. These results suggest that typical Bcl-2 family members are not involved in the permeabilization of the mitochondrial membrane in LBH589-induced apoptosis. Interestingly, LBH589 increased the expression of Bax and PUMA and decreased that of Bcl-2 and Bcl-xL in KK1 cells carrying a non-functional p53 mutation. These results indicate that LBH589 induced apoptosis in ATLL-related cell lines in a p53-independent manner.

Analysis of caspase-2-related apoptotic pathway

CASP2 and RIPK1 domain containing adaptor with death domain (also known as RAIDD), RIP, caspase-9 and cytochrome-c are involved in caspase-2-mediated apoptosis and were upregulated in their expression after LBH589 treatment (Table 1). The apoptosis induced by tumor necrosis factor-R1 requires the adaptor proteins TRADD, RIP and RAIDD in addition to caspase-2. Recent reports suggest that caspase-2 can cause cytochrome-c’s release from mitochondria directly or indirectly. Additionally, PIDD can interact with RAIDD and caspase-2, forming a PIDDosome and inducing apoptosis. We investigated the expression profiles of caspase-2-related proteins by western blotting (Figures 6b and c). Caspase-2 was clearly activated by the treatment with LBH589 and cleaved forms were observed. Similar results were observed in TRAIL-treated Jurkat cells (Figure 6c). PIDD (90kDa) is constitutively processed into 51 and 37kDa forms and cleaved PIDD (37 kDa) is essential for the activation of caspase-2. Furthermore, upregulation of the expression of general forms of PIDD was observed during the activation of caspase-2 induced by genotoxic agents. ATLL cell lines and Jurkat cells expressed various forms of PIDD, levels of which were not increased by LBH589 or TRAIL (Figures 6b and c). RIP was increased and TRADD was decreased in KK1 cells but neither was changed in ST1 or HuT102 cells. Of note, the activation of RAIDD was a common characteristic in these cells. Furthermore, the activation of RAIDD was also observed at the mRNA level in most of the ATLL-related cell lines (Figure 6d). In KK1 and ST1 cells, the activation of RAIDD mRNA expression was faint whereas that of protein production was obvious. We analyzed the 20s proteasome’s activities to investigate whether RAIDD regulation by LBH589 in these cells is due to proteasome inhibition (Supplementary Figure 1C). Activities of 20S proteasome were dramatically impaired by MG132 in all cells examined and were not changed by LBH589 in KK1 and ST1 cells. The activation of RAIDD mRNA was not induced by the various chemicals used except LBH589 (Figure 6d, Supplementary Figure 1C, and data not shown). These results suggest that LBH589 caused the activation of caspase-2 and RAIDD without activating p53 and PIDD. We further observed the activation of RAIDD and caspase-2 in addition to acetylated histones in primary ATLL cells (Figure 6e).

**LBH589 induces apoptosis in ATLL cells via caspase-2’s activation**

To further investigate the role of caspase-2-mediated apoptosis in LBH589-induced cell death, we first performed inhibition...
assays of caspases using specific inhibitors. The proportion of Annexin-V-positive cells among TRAIL-treated Jurkat cells was reduced from 67 to 20% by the pan-caspase inhibitor Z-VAD (Figure 7a). LBH589-induced cell death was also attenuated by Z-VAD with the percentage of Annexin-V-positive cells decreasing from 47 and 54% to 16 and 21% in ST1 and HuT102 cells, respectively. The caspase-8 inhibitor was not effective against LBH589-induced cell death, consistent with the finding that caspase-8 was not activated (Figure 4d). Importantly, the caspase-2 inhibitor Z-VDVAD had a similar effect to Z-VAD in LBH589-treated Jurkat cells, while it had a weak effect in TRAIL-treated cells (46%). Furthermore, western blotting revealed that the cleavage of caspase-3 by LBH589 was inhibited by Z-VDVAD as well as Z-VAD (not shown). These results suggest that LBH589 causes apoptosis in ATLL-related cell lines in a caspase-dependent manner and activation of caspase-2 is essential.

**RAIDD as well as caspase-2 has a critical role in LBH589-induced apoptosis**

Next, we performed siRNA experiments targeting caspase-2, caspase-9, RAIDD, PIDD and RIP to disclose the key triggers of apoptosis. Annexin-V/PI assays revealed that siRNA of RAIDD significantly repressed LBH-induced cell death, as did si-caspase-2 (Figure 7b). The proportion of Annexin-V-positive cells was ~65% in si-control cells and 37% in ST1 si-RAIDD cells. Similar results were obtained with HuT102 cells using siRNA set #1 (Figure 7b), set #2, and set #3 (Supplementary Figure 2C and E). Si-caspase-9 also inhibited LBH589-induced cell death while si-PIDD and si-RIP caused no change (Figure 7b). Similar inhibitory effects by si-RAIDD and si-caspase-2 were observed in JC-1 experiments (Figure 7c). The effect of si-caspase-9 was less extensive than that of si-PIDD or si-RIP (Figure 7c). These results suggest that RAIDD as well as caspase-2 has a critical role in LBH589-induced apoptosis and, importantly, they have active roles upstream of the mitochondria.

**RAIDD has an initiating role in LBH589-induced apoptosis**

Western blotting revealed that si-caspase-2 suppressed the cleavage of caspase-9, caspase-3 and PARP as well as the expression of caspase-2 itself. However, it could not suppress the activation of RAIDD (Figure 7d). Si-caspase-9 suppressed the cleavage of caspase-3 and PARP as well as the expression of caspase-9 itself, but could not suppress the activation of caspase-2 or RAIDD. Of note, si-RAIDD most effectively suppressed the cleavage of caspase-2, caspase-9, caspase-3 and PARP as well as the upregulation of RAIDD expression. Si-PIDD and si-RIP did not alter the expression profiles of caspases and RAIDD. These changes were basically similar in ST1 and HuT102 cells. An additional siRNA experiment was
performed using set #2 and set #3 siRNAs and results were similar to Figure 7d (Supplementary Figure 2D and F). The results indicate that the activation of RAIDD occurs upstream of the activation of caspase-2 and has an initiating role in LBH589-induced apoptosis.

Figure 7 RAIDD has a critical role in initiating LBH589-induced apoptosis. (a) Inhibition assay of caspases. Cells were treated with 25 nM of LBH589 or 100 ng/ml of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) with indicated concentrations of caspase-inhibitors for 24 h. Results were evaluated by Annexin-V/PI staining. Experiments were performed in triplicate and results were expressed as the mean ± s.d. and *P<0.01 compared with si-control. (b) and (c) Effects of siRNA against caspase-2, caspase-9, RAIDD, PIDD and RIP. At 24 h after transfection, cells were incubated for 24 h with either vehicle or 50 nM of LBH589. Results were evaluated using Annexin-V/PI staining or the JC-1 dye and analyzed with flow cytometric analysis. Results were expressed as the mean ± s.d. for three independent experiments and were also analyzed using Student’s t-test. *P<0.01 compared with si-control. (d) Western blotting. At 24 h after transfection, cells were incubated for 24 h with either vehicle or 50 nM of LBH589 and western blotting was performed.

Discussion

DACi achieved significant biological effects in preclinical models of cancer including hematological malignancies which has led to clinical trials.4,47–49 Then, it has become important to re-evaluate the mechanisms of tumor cell death caused by DACi. These processes will improve the design of further clinical trials and help in developing novel DACi. In this study, we showed that a newly developed DACi, LBH589, effectively induces ATLL cell death both in vitro and in vivo by a unique mechanism that has not been reported. Our findings uncovered a new role of casapse-2's activation in the induction of apoptosis.

It has been recognized that caspase-2-mediated apoptosis is initiated by death receptors.42,50 However, recent studies revealed the ability of caspase-2 to engage the intrinsic pathway in response to DNA damage.43,51–53 One possibility is that caspase-2 acts indirectly on the mitochondria, by cleaving the pro-apoptotic protein BID or by activating Bax and inducing the release of cytochrome-c.44 Another alternative is that caspase-2 directly permeabilizes the mitochondrial membrane and stimulates the release of cytochrome-c independently of the Bcl-2 family including Bax and Bcl-2.54 In addition, a recent report indicated that caspase-2 became activated in the so called PIDDosome, a complex of PIDD, caspase-2 and RAIDD, in a p53-dependent manner.55 In our study, si-caspase-2 and si-RAIDD inhibited LBH589-induced apoptosis as well as permeabilization of the mitochondrial membrane. This mechanism is similar to the PIDDosome, however, LBH589-induced apoptosis was independent of p53 and PIDD was not activated. In addition, si-PIDD or si-RIP did not alter LBH589-induced apoptosis. Si-caspase-2 could not suppress the activation of RAIDD while si-RAIDD effectively suppressed the cleavage of caspase-2. These results indicated that LBH589 caused the activation of caspase-2 followed by RAIDD independent of p53 and PIDD. Regarding this point, a previous report suggested that caspase-2’s activation occurred in a p53-independent manner.55 Furthermore, two recent studies using PIDD-deficient mice demonstrated the PIDDosome-independent activation of caspase-2.56,57 From our results, si-caspase-2 attenuated the LBH589-induced permeabilization of the mitochondrial membrane and the mRNA expression of cytochrome-c was highly upregulated by LBH589 probably due to cytochrome-c's release. In contrast, most of the Bcl-2 family proteins were not altered by LBH589. In this regard, Robertson et al. suggested that caspase-2 can directly stimulate the intrinsic pathway independent of the Bcl-2 family.58 More recently, Sidi et al.
demonstrated a caspase-2-dependent apoptotic program that bypasses a deficiency of p53 and excess of Bcl-2. These reports are partly consistent with our own observations. However, our scenario does not work without the activation of RAIDD. Therefore, our results suggest that ATLL cells make use of a unique RAIDD-caspase-2-induced intrinsic pathway, which has not been reported previously. Additionally, as caspase-2-mediated apoptosis requires caspase-9, upregulation of caspase-9 expression by LBH589 is advantageous to the induction of apoptosis. Although a number of independent studies strongly support a role for the intrinsic pathway in DACi-induced apoptosis, the mechanism remains to be fully elucidated. Our findings may provide some explanation.

Although there is a consensus that the p53 pathway is activated by Tax in ATLL cells, we recently found that ATLL-related cell lines expressing the wild-type p53 harbor an intact p53 pathway. Some previous findings highlighted the importance of p53 in the effect of DACi, however, other studies demonstrated that the expression of wild-type p53 is not necessary for DACi-induced apoptosis. Meanwhile, it has been reported that p21, downstream of p53, is activated by DACi independent of p53. Indeed, the expression of p21 was increased by LBH589 in ATLL-related cell lines irrespective of their p53 status. In the present study, we clearly showed that LBH589 does not activate p53 in ATLL-related cell lines with the wild-type p53, and LBH589 was also effective against p53-mutant cells via the induction of a p53-like pro-apoptotic response. A similar phenomenon was reported previously in that the DACi FR901228 caused a p53-like pro-apoptotic response in p53 mutant cells and the degradation of the mutant p53 protein. LBH589 does not activate p53 in ATLL-related cell lines with the wild-type p53, and LBH589 was also effective against p53-mutant cells. These results suggest that some types of DACi including LBH589 act upstream of the p53 pathway and cause the degradation of even mutated p53 protein via an unknown mechanism.

We also explored the ATLL-specific mechanisms in LBH589-induced cell death. Notably, CCR4 and IL-2R, well-known molecular targets in ATLL therapy, were repressed by the LBH589 treatment. We speculated that Tax participates in the suppression of IL-2R, however, cells with high Tax mRNA levels actually showed an increase in Tax mRNA expression after LBH589 treatment. These results indicate that LBH589 can cause apoptosis even in Tax-expressing ATLL cells. In our study, mRNA levels of Tax and HBZ in ATLL-related cell lines were not inversely correlated. In addition, after treatment with LBH589, mRNA levels of Tax and HBZ changed in parallel. These results are not consistent with the idea that HBZ can inhibit Tax’s activation. Meanwhile, the expression of HBZ-SI was suppressed by LBH589 in most of the ATLL-related cell lines. Although the precise function of HBZ-SI is still under investigation, a previous study found that inhibition of HBZ-SI by shRNA resulted in cell growth inhibition in ATLL cells. Thus, HBZ-SI could potentially be a molecular target in ATLL therapy and the decrease in HBZ-SI caused by LBH589 treatment may also contribute to the apoptosis of ATLL cells. Consequently, we demonstrated that LBH589 is a promising drug against ATLL, and also identified a novel intrinsic pathway in LBH589-induced apoptosis.

Conflict of interest
The authors declare no conflict of interest.

Acknowledgements
We would like to express our gratitude to Dr Mesnard JM, Institut de Biologie, Laboratoire Centre d’étude d’agents Pathogènes et Biotechnologies pour la Santé Montpellier, France. Grant support note: This study was supported in part by a Grant-in-aid for Scientific Research (20390580) from the Japan Society for the Promotion of Science and a grant from Novartis.

References
1 Baylin SB, Ohm JE. Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 2: 107–116.
2 Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 9: 769–984.
3 Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 1: 38–51.
4 Xu WS, Parmigiani BR, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 37: 5541–5552.
5 Peart MJ, Tainton KM, Ruelli AA, Dear AE, Sedelies KA, O’Reilly LA et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003; 63: 4460–4471.
6 Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TS) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 2003; 14: 12579–12589.
7 Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101: 4055–4062.
8 Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N et al. The histone deacetylase inhibitor LBH589 is a potent antmyeloma agent that overcomes drug resistance. Cancer Res 2006; 66: 5781–5789.
9 Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4796–4811.
10 Bao Q, Shi Y. Apoptosome: a platform for the activation of initiator caspases. Cell Death Differ 2007; 14: 56–65.
11 Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 2003; 63: 5126–5135.
12 Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F et al. Inhibition of histone deacetylase 6 acetylases and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005; 280: 26729–26734.
13 Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005; 18: 601–607.
14 George P, Bali P, Annanarapu S, Scuto A, Fiskus W, Guo F et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005; 105: 1768–1776.
15 Fiskus W, Pranpat M, Bali P, Balasis M, Kumaraswamy S, Boyapalle S et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 2006; 108: 645–652.
16 Yamada Y, Tomonaga M. The current status of therapy for adult T-cell leukaemia-lymphoma in Japan. Leuk Lymphoma 2003; 44: 611–618.
17 Yoshida M. Discovery of HTLV-1, the first human retrovirus, its unique regulatory mechanisms, and insights into pathogenesis. Oncogene 2005; 24: 5931–5937.
Leukemia

18 Marriott SJ, Semmes OJ. Impact of HTLV-I Tax on cell cycle progression and the cellular DNA repair response. Oncogene 2005; 24: 5986–5995.

19 Gaudry G, Gachon F, Basbous J, Biard-Piechaczky M, Devaux C, Mesnard JM. The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J Virol 2002; 76: 12813–12822.

20 Arnold J, Yamamoto B, Li M, Phipps AJ, Yousif I, Laimire MD et al. Enhancement of infectivity and persistence in vivo by HBZ, a natural antisense coded protein of HTLV-1. Blood 2006; 107: 3976–3982.

21 Cavanagh MH, Landry S, Audet B, Arpin-Andre C, Hivin P, Pare M et al. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci USA 2006; 103: 720–725.

22 Satou Y, Yasunaga J, Yoshida M, Matsuoka M. HTLV-I Tax on cell cycle subnuclear localization. J Virol 2006; 80: 2495–2505.

23 Sunazuka T, Sugahara K, Uemura A, Yamaguchi T, Harasawa H, Yamada Y, Komiyama K, Hayashi M, Ishibashi M, Takatsuka Y et al. Isolation and characterization of T cell leukemia cells. Proc Natl Acad Sci USA 2006; 103: 3979–3984.

24 Mori N, Fujita M, Ikeda S, Yamada Y, Tomonaga M, Ballard DW et al. Constitutive activation of NF-κBp65 in primary adult T-cell leukemia cells. Blood 1999; 93: 2360–2368.

25 Matsuoka M, Jeang KT. Human T-cell leukemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007; 7: 270–280.

26 Mori N, Matsuda T, Tadano M, Kinjo T, Yamada Y, Tsukasaki K et al. Apoptosis induced by the histone deacetylase inhibitor FR901228 in human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. J Virol 2004; 78: 4582–4590.

27 Marinos K, Ikezoe T, Yang J, Komatsu N, Bandobashi K, Taniguchi A et al. Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-I-infected T-cells via blockade of signaling by nuclear factor kappaB. Leuk Res 2008; 32: 287–296.

28 Huan D, Dixin VM. RAIDD is a new ‘death’ adaptor molecule. Nature 1997; 385: 86–89.

29 Robertson JD, Enoksson M, Suomela M, Zhivotovsky B, Orrenius S. Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis. J Biol Chem 2002; 277: 29903–29909.

30 Guo Y, Srinivasula SM, Drulhe A, Fernandes-Alnemri T, Alnemri ES. Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J Biol Chem 2002; 277: 13430–13437.

31 Tinel A, Tschopp J. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science 2004; 304: 843–846.

32 Mori N, Fujii M, Ikeda S, Yamada Y, Tomonaga M, Ballard DW et al. Constitutive activation of NF-κBp65 in primary adult T-cell leukemia cells. Blood 1999; 93: 2360–2368.

33 Matsuoka M, Jeang KT. Human T-cell leukemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007; 7: 270–280.

34 Nishioka C, Ikezoe T, Yang J, Komatsu N, Bandobashi K, Taniguchi A et al. Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-I-infected T-cells via blockade of signaling by nuclear factor kappaB. Leuk Res 2008; 32: 287–296.

35 Huan D, Dixin VM. RAIDD is a new ‘death’ adaptor molecule. Nature 1997; 385: 86–89.

36 Twin A, Tschopp J. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science 2004; 304: 843–846.

37 Yoshie O, Fujisawa R, Nakayama T, Harasawa H, Tago H, Izawa D et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-infected T cells. Blood 2002; 99: 1505–1511.

38 Mori N, Fujita M, Ikeda S, Yamada Y, Tomonaga M, Ballard DW et al. Constitutive activation of NF-κBp65 in primary adult T-cell leukemia cells. Blood 1999; 93: 2360–2368.

39 Matsuoka M, Jeang KT. Human T-cell leukemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007; 7: 270–280.

40 Mori N, Matsuda T, Tadano M, Kinjo T, Yamada Y, Tsukasaki K et al. Apoptosis induced by the histone deacetylase inhibitor FR901228 in human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. J Virol 2004; 78: 4582–4590.

41 Nishioka C, Ikezoe T, Yang J, Komatsu N, Bandobashi K, Taniguchi A et al. Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-I-infected T-cells via blockade of signaling by nuclear factor kappaB. Leuk Res 2008; 32: 287–296.

42 Huan D, Dixin VM. RAIDD is a new ‘death’ adaptor molecule. Nature 1997; 385: 86–89.

43 Robertson JD, Enoksson M, Suomela M, Zhivotovsky B, Orrenius S. Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis. J Biol Chem 2002; 277: 29903–29909.

44 Guo Y, Srinivasula SM, Drulhe A, Fernandes-Alnemri T, Alnemri ES. Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J Biol Chem 2002; 277: 13430–13437.

45 Tinel A, Tschopp J. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science 2004; 304: 843–846.

46 Mori N, Fujii M, Ikeda S, Yamada Y, Tomonaga M, Ballard DW et al. Constitutive activation of NF-κBp65 in primary adult T-cell leukemia cells. Blood 1999; 93: 2360–2368.

47 Twin A, Tschopp J. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science 2004; 304: 843–846.

48 Rasheed W, Bishton M, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. EMBO J 2003; 22: 375–382.

49 Rosato RR, Grant S. Histone deacetylase inhibitors in cancer therapy. EMBO J 2003; 22: 375–382.

50 Ahmad M, Srinivasula SM, Wang L, Talanian RV, Litwack G, Fernandes-Alnemri T et al. CRADD, a novel human apoptotic adaptor molecule for caspase-2, and FasL/tumor necrosis factor receptor-interacting protein RIP. Cancer Res 1997; 57: 615–619.

51 Lassus P, Opitz-Araya X, Lazezinnk Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 2002; 297: 1352–1354.

52 Zhivotovsky B, Orrenius S. Caspase-2 function in response to DNA damage. Biochem Biophys Res Commun 2005; 331: 859–867.

53 Mhaidat NM, Wang Y, Kiejda KA, Zhang XD, Hersey P. Docetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2. Mol Cancer Ther 2007; 6: 752–761.

54 Robertson JD, Gogvatze V, Kropotov A, Vakifahmetoglu H, Zhivotovsky B, Orrenius S. Processed caspase-2 can induce mitochondria-mediated apoptosis independently of its enzymatic activity. EMBO Rep 2004; 5: 643–648.

55 Castedo M, Perretini JL, Roumier T, Valient A, Raslova H, Yakushijin K et al. Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene 2004; 23: 4362–4369.

56 Marinos K, Ikezoe T, Yang J, Komatsu N, Bandobashi K, Taniguchi A et al. Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-I-infected T-cells via blockade of signaling by nuclear factor kappaB. Leuk Res 2008; 32: 287–296.

57 Kim IR, Murakami K, Chen NJ, Saibai SD, Matsyiak-Zhalocki E, Ellord AR et al. DNA damage- and stress-induced apoptosis occurs independently of PIDD. Apoptosis 2009; 14: 1039–1049.
58 Sidi S, Sanda T, Kennedy RD, Hagen AT, Jette CA, Hofmans R et al. Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell 2008; 133: 864–877.

59 Pise-Masison CA, Jeong SJ, Brady JN. Human T cell leukemia virus type 1: the role of Tax in leukemogenesis. Arch Immunol Ther Exp (Warsz) 2005; 53: 283–296.

60 Rueffli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Koeller R et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001; 98: 10833–10838.

61 Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nature Med 2005; 11: 71–76.

62 Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000; 97: 10014–10019.

63 Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004; 101: 1241–1246.

64 Blagosklonny MV, Trostel S, Kayastha G, Demidenko ZN, Vassilev LT, Romanova LY et al. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res 2005; 65: 7386–7392.

65 Ishida T, Ueda R. CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 2006; 11: 1139–1146.

66 Chen J, Zhang M, Ju W, Waldmann TA. Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25. Blood 2009; 113: 1287–1293.

This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)